Statins are the most prescribed cardiovascular drugs in the world, and muscle pain is the single most common reason people stop taking them. On 1 August 2026, researchers at McMaster University published work that finally puts a mechanism behind those symptoms — and it is not the one most doctors were taught.
The finding matters for anyone reading a lab report, because it changes how you should think about one specific line on it: creatine kinase, usually printed as CK or CPK.
What the new study actually found
The team, led by Jonathan Schertzer at McMaster’s Department of Biochemistry and Biomedical Sciences, reported in Science Advances that statins interfere with the way muscle cells produce energy. That metabolic disruption trips an internal alarm system called the NLRP3 inflammasome — essentially an immune switch that sits inside the muscle cell itself.
Once that switch flips, the cell starts damaging itself. In muscle cells and in mice, blocking the NLRP3 pathway prevented most of the damage. Restoring a family of molecules called isoprenoids also worked. Restoring cholesterol did not.
That last detail is the important one. It means the pathway causing muscle symptoms is separate from the pathway that lowers your cholesterol. In practical terms: the muscle problem is not the price you pay for the cholesterol benefit. They are two different roads that happen to start at the same drug.
An estimated 7 to 29 percent of statin users report muscle symptoms — pain, weakness, cramps, or simply not being able to exercise the way they used to. Until now, the explanation was vague. It now has a name and a set of molecular targets.
Why this lands on your blood test
Creatine kinase is an enzyme that lives inside muscle fibres. When muscle cells are stressed or breaking down, CK leaks into the blood and the level on your report climbs. That makes it the standard test a doctor orders when muscle symptoms appear during statin treatment. Our full guide to the CPK blood test and what high creatine kinase means covers the marker itself in detail.
What the McMaster work adds is a reason why CK behaves so unhelpfully in this exact situation. The damage described in the study is low-level and cell-autonomous — muscle cells quietly injuring themselves through an immune pathway. That kind of injury does not necessarily dump enough enzyme into the bloodstream to push CK above a laboratory threshold. Which is why a large share of people with genuine statin-associated muscle symptoms have a CK result that looks entirely normal.
A normal CK does not mean your symptoms are imaginary. It means CK was never designed to detect what is happening to you.
How to read a CK result during statin treatment
Reference ranges vary between laboratories, so results are usually interpreted as multiples of the upper limit of normal, written as ULN or N. The table below reflects how clinicians generally read the number.
| CK result | Usual reading | What typically happens |
|---|---|---|
| Within range, symptoms present | Common in statin-associated muscle symptoms | Symptoms are assessed clinically, not by the number |
| Mildly raised, under 5x ULN | Often exercise, injury or individual variation | Retest after rest; treatment often continued |
| Above 5x ULN | Betydande muskelskada | Statin usually paused and the cause investigated |
| Very high, tens of thousands | Rabdomyolys | Urgent care; kidney function checked immediately |
Two practical points change how much a single CK value is worth. First, CK is exquisitely sensitive to physical activity — a hard workout, a long hike, even an intramuscular injection can raise it for days, which is why blood should be drawn well away from intense exercise. Second, individual baselines differ enormously; some healthy people simply run high.
CK also comes in forms. The version that reflects heart muscle is a different measurement altogether, explained in our page on the CK-MB test and why troponin replaced it. When skeletal muscle breaks down rapidly, another protein rises alongside CK, covered in our guide to myoglobin as a muscle marker.
The liver result that is not your liver
Here is the trap that sends people into needless panic. Substantial muscle breakdown releases AST — an enzyme most people know as a liver marker — into the blood. Someone on a statin who sees a raised AST often concludes the drug has damaged their liver, when the enzyme actually came out of muscle.
The pattern is usually recognisable: AST rises noticeably while ALT moves far less, and CK is elevated at the same time. Our explainer on reading the AST/ALT ratio walks through how that distinction is made. If muscle breakdown is severe, kidney markers matter too, which is where urine creatinine as a yardstick becomes relevant.
When muscle symptoms are not ordinary statin intolerance
Most statin muscle symptoms are mild, reversible and settle after a dose change or a switch to another statin. A small number are something else entirely, and the distinction is made in the laboratory.
- Immune-mediated necrotizing myopathy: a rare autoimmune reaction in which CK stays high even after the statin is stopped, with progressive weakness. It is confirmed by an antibody test against HMG-CoA reductase.
- Rhabdomyolysis: massive muscle breakdown with severe pain, weakness and dark urine. Case reports document CK values from roughly 3,000 to over 47,000 U/L, frequently with acute kidney injury.
- Drug interactions: certain medications raise statin levels in the blood and multiply the muscle risk. Documented examples include some cancer therapies, azole antifungals and fibrates.
- Untreated hypothyroidism, kidney impairment and heavy alcohol use all increase susceptibility, which is why thyroid and kidney function are often checked alongside CK.
Latest scientific advances, in plain terms
Three threads from the recent literature are worth knowing about, none of which require you to read a statistics table.
The first is that specialists now largely agree there is no single blood test that proves a muscle symptom is caused by a statin. Reviews of statin-associated muscle symptoms describe diagnosis as a clinical process — stop, observe, restart carefully, observe again — with CK used as a safety check rather than as proof.
The second is that structured rechallenge works more often than people expect. A large proportion of those who abandon statins can tolerate a lower dose, a different statin, or an alternate-day schedule. Because the McMaster work suggests the muscle pathway is separable from the cholesterol pathway, this reasoning now has a mechanism behind it.
The third is that when a statin genuinely cannot be tolerated, alternatives exist and have been compared head to head. A network meta-analysis of more than 100,000 patients found that certain injectable cholesterol-lowering treatments produced fewer new muscle symptoms and fewer episodes of markedly raised CK than others. That comparison is a conversation to have with your doctor, not a reason to change anything on your own.
What to do if this is you
If muscle symptoms started or worsened after beginning a statin or increasing the dose, tell your doctor rather than stopping the drug yourself. Stopping abruptly removes a proven protection against heart attack and stroke, and the underlying reason you were prescribed it has not gone away — as our overview of high cholesterol, targets and treatment beskriver.
Note when symptoms began, which muscles are involved, and whether you have started any new medication or supplement. Mention any intense exercise in the days before your blood draw. Ask whether thyroid function should be checked at the same time. And bring your full lipidpanel to the conversation, because the decision about what to do next depends on how much cardiovascular risk the drug is offsetting — a calculation that recently changed, as we covered in the new LDL cholesterol calculation on lab reports.
Dark urine, severe weakness or pain that stops you moving normally is different. That combination warrants urgent medical attention the same day.
Vanliga frågor
Can my CK be normal even though the statin is causing my symptoms?
Yes, and it commonly is. The mechanism described by the McMaster team produces low-level muscle injury that does not always release enough enzyme to exceed a laboratory threshold. A normal CK rules out serious muscle destruction; it does not rule out statin-associated muscle symptoms.
Should I have my CK checked before starting a statin?
Routine testing in everyone before treatment is not generally recommended. A baseline is useful in specific situations: kidney impairment, hypothyroidism, a personal or family history of muscle disease, a previous muscle reaction to a statin or fibrate, heavy alcohol use, or older age with additional risk factors.
How long after exercise should I wait before a CK test?
At least two days after any intense muscular effort, and longer after unaccustomed or eccentric exercise. A notably raised result is usually rechecked within about a week to see whether it is falling.
Will the muscle pain go away if I stop the statin?
In the large majority of cases symptoms resolve after the drug is stopped, though they can take weeks to months to fade completely. Symptoms that persist, or a CK that stays high after stopping, should prompt a search for another cause, including autoimmune myopathy.
Does this study mean a treatment is coming?
Not yet. Identifying the NLRP3 pathway gives drug developers a target, and the authors are explicit that more research is needed before any of this reaches patients. The immediate value is diagnostic clarity, not a new prescription.
Ordlista
- Creatine kinase (CK, CPK): an enzyme found inside muscle cells that leaks into the blood when muscle is damaged.
- ULN: upper limit of normal, the top of the laboratory reference range. Results are often described as multiples of it.
- NLRP3 inflammasome: a protein complex inside cells that acts as an alarm, triggering inflammation when it detects danger signals.
- Isoprenoids: molecules made along the same production line as cholesterol, needed to attach certain proteins to cell membranes.
- Statin-associated muscle symptoms (SAMS): the umbrella term for muscle pain, weakness, cramps or tenderness reported during statin treatment.
- Rhabdomyolysis: rapid, extensive breakdown of muscle tissue that can overwhelm the kidneys.
- HMG-CoA reductase: the enzyme statins block to lower cholesterol production, and the target of the antibody found in immune-mediated necrotizing myopathy.
Understand your own results
A CK value means very little on its own. It only becomes useful next to your transaminases, your kidney markers, your thyroid results and the medication you are taking. AI DiagMe reads your complete lab report and explains, line by line, what each result means in your specific context — including which numbers are consistent with muscle rather than liver origin. Upload your report at aidiagme.com to get a clear, plain-language interpretation before your next appointment.
Vidare läsning
- Utökad lipidpanel: vad den mäter och vem som behöver den
- Normal LDL levels: why there is no single healthy range
- Lipoprotein(a) screening for every adult
- The blood tests that decide whether you need blood pressure medication
- Muscle loss, eGFR and the cystatin C test
Källor
- McMaster University. Scientists may have found a way to prevent statin muscle pain. ScienceDaily, 1 August 2026. sciencedaily.com
- Robin N, Barra NG, Foley KP, et al. Statins promote muscle metabolic danger and NLRP3-mediated myopathy via lower protein-prenylation and YAP. Science Advances. 2026;12(25):eadz3612. DOI — PubMed
- Cha J, et al. Diagnosis and Management of Statin-Associated Muscle Symptoms. Korean Circulation Journal. 2025. Reference
- Shah M, et al. Statin-associated muscle symptoms: a comprehensive exploration of epidemiology, pathophysiology, diagnosis, and clinical management strategies. International Journal of Rheumatic Diseases. 2024. Reference
- Li W, Sun Y, Yan J. PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a systematic review and network meta-analysis. Frontiers in Cardiovascular Medicine. 2024. Reference
- Zhao C, Duffield A, Toz B. Anti-HMGCR immune-mediated necrotizing myopathy with subsequent diagnosis of mantle cell lymphoma. Cureus. 2026;18(5):e108086. DOI
- Nguyen M, et al. Delayed-onset rhabdomyolysis of bilateral lower extremities following statin therapy. American Journal of Case Reports. 2025;26:e948601. DOI
- João RB, Soares LR, Ragazzo PC, Freitas-Junior R. CDK4/6 inhibitor-statin interaction and rhabdomyolysis in breast cancer treatment: a case-based systematic review. Cancer Chemotherapy and Pharmacology. 2026;96(1). DOI
